A Phase 2, Open Label, 2-Cohort, Multi-center Study of INCB50465, a P13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with or Without a BTK Inhibitor
A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy
Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma
An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer
A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy